JP2022080275A - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- JP2022080275A JP2022080275A JP2021175072A JP2021175072A JP2022080275A JP 2022080275 A JP2022080275 A JP 2022080275A JP 2021175072 A JP2021175072 A JP 2021175072A JP 2021175072 A JP2021175072 A JP 2021175072A JP 2022080275 A JP2022080275 A JP 2022080275A
- Authority
- JP
- Japan
- Prior art keywords
- ingestion
- weeks
- trapa
- composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 35
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims abstract description 21
- 241001428357 Trapa japonica Species 0.000 claims description 24
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 19
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 18
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 18
- 235000012661 lycopene Nutrition 0.000 claims description 18
- 239000001751 lycopene Substances 0.000 claims description 18
- 229960004999 lycopene Drugs 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 18
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 18
- 241001083492 Trapa Species 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 11
- 240000001085 Trapa natans Species 0.000 claims description 6
- 235000014364 Trapa natans Nutrition 0.000 claims description 6
- 244000243786 Trapa incisa Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 241000227653 Lycopersicon Species 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 26
- 230000003078 antioxidant effect Effects 0.000 abstract description 23
- 238000005810 carbonylation reaction Methods 0.000 abstract description 19
- 238000006243 chemical reaction Methods 0.000 abstract description 19
- 240000003768 Solanum lycopersicum Species 0.000 abstract description 17
- 230000003712 anti-aging effect Effects 0.000 abstract description 15
- 230000032683 aging Effects 0.000 abstract description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 12
- 238000007254 oxidation reaction Methods 0.000 abstract description 12
- 239000001301 oxygen Substances 0.000 abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 abstract description 12
- 241000196324 Embryophyta Species 0.000 abstract description 10
- 230000006315 carbonylation Effects 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 4
- 230000037406 food intake Effects 0.000 description 87
- 210000003491 skin Anatomy 0.000 description 28
- 235000006708 antioxidants Nutrition 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000021194 placebo diet Nutrition 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000002904 solvent Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 235000021195 test diet Nutrition 0.000 description 9
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 8
- -1 aldehyde compounds Chemical class 0.000 description 7
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 7
- 235000013734 beta-carotene Nutrition 0.000 description 7
- 239000011648 beta-carotene Substances 0.000 description 7
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 7
- 229960002747 betacarotene Drugs 0.000 description 7
- 235000021466 carotenoid Nutrition 0.000 description 7
- 150000001747 carotenoids Chemical class 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 7
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 3
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 108091006003 carbonylated proteins Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 235000011765 phytoene Nutrition 0.000 description 3
- 235000002677 phytofluene Nutrition 0.000 description 3
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 description 3
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000008601 oleoresin Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 150000002927 oxygen compounds Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000001930 Autoimmune limbic encephalitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000003483 aging Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002635 aromatic organic solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- 238000003877 atomic layer epitaxy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013573 potato product Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Images
Landscapes
- Jellies, Jams, And Syrups (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Description
本発明は、ヒシ属植物の加工物及び抗酸化物を含有する組成物を提供する。 The present invention provides a processed product of Trapa japonica and a composition containing an antioxidant.
糖化反応は、還元糖のカルボニル基と蛋白質又はアミノ酸のアミノ基が非酵素的に縮合する反応で、シッフ塩基を経由して、アマドリ転移産物を生成する前期反応と、その後、アマドリ転移産物が分解され、さらに脱水、酸化、縮合、転移等の過程を経て、終末糖化産物群(AGEs)へと変化する後期反応とに分けられる。食品の加工、貯蔵の際に起こる褐変反応として食品科学の分野では古くからよく知られる現象である。 The saccharification reaction is a reaction in which the carbonyl group of advanced glycation end and the amino group of a protein or amino acid are non-enzymatically condensed. It is further divided into a late reaction that changes to advanced glycation end products (AGEs) through processes such as dehydration, oxidation, condensation, and rearrangement. It is a phenomenon that has long been well known in the field of food science as a browning reaction that occurs during the processing and storage of food.
この反応は生体内でも起こっており、AGEsが加齢に依存して種々の生体組織に蓄積すること、また、糖尿病合併症、アルツハイマーや動脈硬化などの加齢関連疾患で、AGEsの蓄積が有意に増加していることが報告されている。さらに、糖化反応は、加齢に伴って生じる白内障や軟骨の弾力低下、しわ、たるみや黄ぐすみなどの皮膚の老化の原因となり、特に常時高血糖状態である糖尿病患者においてその進行が早いことが報告されている。 This reaction also occurs in vivo, and AGEs accumulate in various biological tissues depending on aging, and the accumulation of AGEs is significant in age-related diseases such as diabetic complications, Alzheimer's disease and arteriosclerosis. It has been reported that the number has increased. Furthermore, the glycation reaction causes aging of the skin such as cataracts, decreased cartilage elasticity, wrinkles, sagging and yellowing that occur with aging, and the progress is particularly rapid in diabetic patients who are constantly hyperglycemic. Has been reported.
このため、糖化反応を阻害する物質は、生体内の様々な加齢関連疾患の抑制や糖尿病合併症を抑制し得ると考えられ、そのような物質を求めて種々の研究がされている。 Therefore, it is considered that a substance that inhibits the glycation reaction can suppress various age-related diseases and diabetic complications in the living body, and various studies have been conducted in search of such a substance.
例えば、ヒシ属植物の果皮を熱水抽出したヒシ属植物の抽出物、特にトウビシ抽出物は、ヒシエキスと呼ばれ強力な糖化抑制作用を有することが知られている(例えば特許文献1参照)。 For example, an extract of a trapa japonica plant obtained by hot-water-extracting the peel of a trapa japonica plant, particularly a trapa japonica extract, is called trapa japonica extract and is known to have a strong inhibitory effect on saccharification (see, for example, Patent Document 1).
しかしながら、これまでの糖抑制作用を有する組成物では、アンチエイジングとしての効果は十分とは言えず、効果の一段と高いアンチエイジング作用を有する組成物が要望されていた。 However, the conventional compositions having a sugar-suppressing effect cannot be said to have a sufficient anti-aging effect, and a composition having a higher anti-aging effect has been desired.
本発明は、高いアンチエイジング効果を呈する組成物を提供することを目的とする。 An object of the present invention is to provide a composition exhibiting a high anti-aging effect.
かかる課題を解決するため、本発明の組成物は、ヒシ属植物の加工物とトマト抽出エキスとを含有する。 In order to solve such a problem, the composition of the present invention contains a processed product of Trapa japonica and a tomato extract.
本発明は、高いアンチエイジング効果を呈する組成物を実現できる。 The present invention can realize a composition exhibiting a high anti-aging effect.
上述したように、タンパク質の糖化反応は終末糖化産物群(AGEs:Advanced Glycation End-products)の蓄積を引き起こし、生体の老化の原因となる。 As described above, the glycation reaction of proteins causes the accumulation of advanced glycation end products (AGEs) and causes the aging of the living body.
また、タンパク質のカルボニル化は、主要なタンパク質損傷の一つである。カルボニルタンパク質は、アミノ酸側鎖の酸化的分解や脂質の過酸化反応によって生じるアルデヒド化合物の付加によって脂質過酸化最終生成物(ALEs:Advanced lipoxidation products)が生成されることが確認されている。 Also, protein carbonylation is one of the major protein damages. It has been confirmed that carbonyl proteins produce lipid peroxidation final products (ALEs: Advanced lipoxidation products) by the addition of aldehyde compounds generated by the oxidative decomposition of amino acid side chains and the peroxidation reaction of lipids.
皮膚最外層に位置する角層は水分を保持し、蒸散をバリアするなど生物学的に重要であるだけでなく、実際に目で見ているという意味で化粧品学的にも重要な部分である。その角層は角層細胞と細胞間脂質から構成され、ケラチンと呼ばれるタンパク質が角層細胞の主成分となっている。 The stratum corneum, which is located in the outermost layer of the skin, is not only biologically important because it retains water and barriers to transpiration, but it is also a cosmetically important part in the sense that it is actually seen by the eyes. .. The stratum corneum is composed of stratum corneum cells and intercellular lipids, and a protein called keratin is the main component of stratum corneum cells.
近年、過酸化脂質の分解物であるアクロレインなどのアルデヒド類が、タンパク質に付加してタンパク質をカルボニル化させることが知られるようになってきた。アルツハイマー病や動脈硬化など酸化が関与すると考えられている病態では、カルボニル化によってタンパク質が本来の機能を失い、蓄積していると考えられている。また、光線性弾力線維症では、真皮成分におけるカルボニル化タンパク質の増加が観察されている。一方、外界の影響を受けやすい角層の主タンパク質、ケラチンにおいてもカルボニル化タンパク質が存在していることが明らかになっている。 In recent years, it has become known that aldehydes such as acrolein, which is a decomposition product of lipid peroxide, are added to proteins to carbonylate the proteins. In pathological conditions such as Alzheimer's disease and arteriosclerosis, which are thought to be involved in oxidation, it is thought that proteins lose their original functions and accumulate due to carbonylation. In addition, in actinic elastosis, an increase in carbonylated protein in the dermis component has been observed. On the other hand, it has been clarified that the carbonylated protein is also present in keratin, the main protein of the stratum corneum, which is easily influenced by the outside world.
紫外線などの外的要因やストレスなどの内的要因など様々な原因により、生体内で活性酸素が発生する。活性酸素種やフリーラジカルは、生体の恒常性維持に欠かせない生理活性物質であると同時に、過剰に存在すると核酸、たんぱく質、脂質を酸化することにより生体に有害な影響を及ぼすことが知られている。 Active oxygen is generated in the living body due to various causes such as external factors such as ultraviolet rays and internal factors such as stress. Reactive oxygen species and free radicals are physiologically active substances that are indispensable for maintaining homeostasis of the living body, and at the same time, it is known that when they are present in excess, they have harmful effects on the living body by oxidizing nucleic acids, proteins, and lipids. ing.
皮膚においても酸化ストレスは、様々な皮膚症状、がん、老化などに密接に関わっている。 Oxidative stress is also closely associated with various skin symptoms, cancer, aging, etc. in the skin.
平均寿命の延びや少子高齢化の進行に伴い、健康を維持しつつ長生きするために、抗加齢いわゆるアンチエイジングへの関心が高まっている中、優れたアンチエイジング効果を有し、かつ安全性の高い機能性食品や化粧品素材等の開発が切望されている。 With the increase in life expectancy and the declining birthrate and aging population, there is growing interest in anti-aging, so-called anti-aging, in order to maintain good health and live longer. The development of highly functional foods and cosmetic materials is eagerly desired.
本発明は、アンチエイジングとして、糖化反応・カルボニル化反応・活性酸素の作用の3つに着目し、ヒシ属植物の加工物と強力な抗酸化物とを組み合わせて使用することで、3大老化現象と呼ばれている生体内の糖化、カルボニル化、酸化の3つを、同時にかつ効果的に抑制する組成物を見出した。 The present invention focuses on the three actions of saccharification reaction, carbonylation reaction, and active oxygen as anti-aging, and by using a processed product of Trapa plants and a strong antioxidant in combination, three major agings occur. We have found a composition that simultaneously and effectively suppresses the three phenomena called glycation, carbonylation, and oxidation in the living body.
すなわち本発明は、図1に示すように、酸化反応を抑制及び分解することにより酸化反応自体を抑制したり、血糖値を抑制して糖の血中濃度を低減したりする作用を有するヒシ属植物と、活性酸素を除去する効果のある抗酸化物とを組み合わせた組成物である。この結果、酸化反応を抑制しつつ、活性酸素の減少による酸化反応自体の抑制を可能とし、結果として生体内の糖化、カルボニル化、酸化の3つを同時にかつ効果的に抑制する組成物を実現することが可能となる。なお図中では、ヒシ属植物を「ヒシ」、抗酸化物を「抗酸」と表記している。 That is, as shown in FIG. 1, the present invention has the effect of suppressing the oxidative reaction itself by suppressing and decomposing the oxidative reaction, and suppressing the blood glucose level to reduce the blood concentration of sugar. It is a composition in which a plant and an antioxidant having an effect of removing active oxygen are combined. As a result, it is possible to suppress the oxidation reaction itself by reducing the amount of active oxygen while suppressing the oxidation reaction, and as a result, a composition that simultaneously and effectively suppresses glycation, carbonylation, and oxidation in the living body is realized. It becomes possible to do. In the figure, the trapa japonica plant is referred to as "trapa japonica" and the antioxidant is referred to as "antioxidant".
ヒシ属植物としては、特に制限されないが、例えばヒシ(Trapajaponica)、トウビシ(TrapabispinosaRoxb)、オニビシ(TrapanatansL.ver.Japonica)及びヒメビシ(Trapaincisa)などが好適に使用可能である。 The plant of the genus Trapa is not particularly limited, and for example, Trapa japonica, TrapabispinosaRoxb, TrapanatansL.ver.Japonica, Trapaincisa and the like can be preferably used.
ヒシ属植物としては、果皮及び果実の一方又は双方の成分を含有する。抽出方法に制限は無いが、有機溶媒又は熱水による溶媒抽出により分離された有効成分のエキスが好適に使用される。 The Trapa japonica plant contains components of one or both of the pericarp and the fruit. The extraction method is not limited, but an extract of the active ingredient separated by solvent extraction with an organic solvent or hot water is preferably used.
ヒシ科植物の果実及び果皮は、生の実又は生の実から採取したもの、採取後乾燥したもの、乾燥した実又は乾燥した実から採取したもののいずれであってもよく、抽出効率を向上させるために、溶媒抽出の前に任意の方法を用いて破砕又は粉砕等の前処理を行ってもよい。 The fruits and pericarps of Trapaceae plants may be collected from raw fruits or raw fruits, dried after collection, dried fruits or dried fruits, and improve extraction efficiency. Therefore, pretreatment such as crushing or crushing may be performed by any method before solvent extraction.
ヒシ属植物の果皮を熱水抽出したヒシ属植物の抽出物、特にトウビシ抽出物は、ヒシエキスと呼ばれ糖化抑制作用を有することが知られている。糖化作用により生じる終末糖化産物は、コラーゲン、エラスチン等の生体タンパク質の変性と機能低下を引き起こすことで、様々な老化現象や疾病の発現に関与することも知られている。この糖化作用を抑制することで、生体の老化、特に皮膚の老化の予防が期待されるため、トウビシ抽出物は化粧品等に配合されている。 An extract of a trapa japonica plant obtained by hot water extraction of the peel of a trapa japonica plant, particularly a trapa japonica extract, is called a trapa japonica extract and is known to have a saccharification inhibitory effect. Advanced glycation end products produced by saccharification are also known to be involved in the development of various aging phenomena and diseases by causing denaturation and functional deterioration of biological proteins such as collagen and elastin. By suppressing this saccharification action, it is expected to prevent the aging of the living body, particularly the aging of the skin. Therefore, the Tobishi extract is blended in cosmetics and the like.
抗酸化物としては、活性酸素およびフリーラジカルの消去を行う予防的抗酸化剤と、ラジカルによる過酸化反応の連鎖開始反応を抑制する、あるいは過酸化反応の連鎖成長反応を阻止するラジカル捕捉型抗酸化剤の一方又は両方が適宜選択して使用される。 Antioxidants include prophylactic antioxidants that scavenge active oxygen and free radicals, and radical-capturing antioxidants that suppress the chain initiation reaction of peroxidation reactions by radicals or inhibit the chain growth reaction of peroxidation reactions. One or both of the oxidizing agents are appropriately selected and used.
抗酸化物としては、特に制限されず、公知の化合物を使用することが可能である。好ましくは、スーパーオキシドアニオン(O2)、ヒドロキシラジカル(・OH)、一酸化窒素ラジカル(NO・)、次亜塩素酸イオン(ClO)、過酸化水素(H2O2)、一重項酸素(1O2)など、フリーラジカルを保有する又はフリーラジカルを容易に生成可能な状態にある低分子(分子量100以下)の酸素化合物、いわゆる活性酸素を除去(失効)可能なポリフェノールやカロテノイドが使用される。 The antioxidant is not particularly limited, and known compounds can be used. Preferably, superoxide anion (O2), hydroxy radical (.OH), nitrogen monoxide radical (NO.), Hypochlorite ion (ClO), hydrogen peroxide (H2O2), singlet oxygen (1O2), etc. Low-molecular-weight (molecular weight 100 or less) oxygen compounds that have free radicals or are in a state where free radicals can be easily generated, so-called polyphenols and carotenoids that can remove (revoke) active oxygen, are used.
カロテノイドとしては、特にα-カロテン、β-カロテン、β-クリプトキサンチン、ルテイン、ゼアキサンチン、およびリコピンなどのカロテン類やキサントフィル類が好適に使用される。特にリコピンは、一重項酸素の除去について、β-カロテンを含めたすべてのカロテノイドの中で最も高い活性を有しており、リコピンの抗酸化活性は、β-カロチンの約3.2倍であり、ビタミンEの約100倍である。経口投与されて腸管を介して吸収されると、リコピンは遊離ラジカルを除去し、遊離ラジカルによる酸化から組織、細胞およびDNAを保護する。 As the carotenoid, carotenes such as α-carotene, β-carotene, β-cryptoxanthin, lutein, zeaxanthin, and lycopene and xanthophylls are particularly preferably used. In particular, lycopene has the highest activity among all carotenoids including β-carotene for the removal of singlet oxygen, and the antioxidant activity of lycopene is about 3.2 times that of β-carotene. , About 100 times that of vitamin E. When administered orally and absorbed through the intestinal tract, lycopene removes free radicals and protects tissues, cells and DNA from oxidation by free radicals.
人体におけるリコピンの主な標的器官および標的組織は、精巣、前立腺、肝臓および腸である。リコピンは、前立腺癌、子宮癌および膵癌の発症率を、β-カロテンより有効に低下させることが知られている。 The main target organs and tissues of lycopene in the human body are the testis, prostate, liver and intestine. Lycopene is known to effectively reduce the incidence of prostate, uterine and pancreatic cancers over β-carotene.
これまでの研究によって、リコピンの多くの機能:老化防止、免疫による健康状態の向上、循環器疾患の危険率の低下、および悪性腫瘍(特に口腔がん、咽頭がん、胃がん、大腸がんおよび子宮がん)の発症率の低下が明らかにされている。47000人の参加者を含んでいる、ハーバード大学において6年間にわたって実施された網羅的な解析によって、前立腺がんの発症率はリコピン群において30%を超えて低下したことが確認されている。さらに、臨床試験によって、膵がん、肺がんおよび胃がんにとって特に有効な、腫瘍の成長および転移の抑制におけるリコピンの活性が明らかにされている。 Previous studies have shown that many functions of lycopene: antiaging, improving immune health, reducing the risk of cardiovascular disease, and malignant tumors (especially oral, pharyngeal, gastric, colon, and colon cancers). It has been shown that the incidence of uterine cancer) is reduced. A comprehensive analysis conducted over 6 years at Harvard University, which includes 47,000 participants, confirms that the incidence of prostate cancer was reduced by more than 30% in the lycopene group. In addition, clinical trials have revealed the activity of lycopene in suppressing tumor growth and metastasis, which is particularly effective for pancreatic, lung and gastric cancers.
その有益な複数の作用のために、リコピンは、21世紀における優れた健康食品補助剤として現在、認識されており、世界中で関心を集めている。特に米国、西ヨーロッパ、日本およびイスラエルを含む先進国において、1990年以来、膨大な資産および労力が、関連する研究、ならびにリコピンを含んでいる薬物、食品補助剤、食品および化粧品の開発に注ぎ込まれている。 Due to its beneficial effects, lycopene is now recognized as an excellent health food supplement in the 21st century and is of interest worldwide. Since 1990, vast assets and efforts have been devoted to relevant research and the development of drugs, food supplements, foods and cosmetics containing lycopene, especially in developed countries including the United States, Western Europe, Japan and Israel. ing.
抗酸化物としては、トマト抽出エキスを使用することが好ましい。トマト抽出エキスとしては、リコピンの他に、β-カロテン、トコフェロール、フィトステロール、フォスフォリピッド、フィトエン、フィトフルエンなどの天然化合物を含んでいることが好ましい(必須ではない)。ポリフェノールを含むことが特に好ましい、抗酸化物としての相互作用が期待できるからである。トマト抽出エキス中のリコピンの含有量(HPLC法)は、1%~50%、さらには10%~30%であることが好ましい。少量の摂取で高い効果が期待できるからである。また、トマト抽出エキス中の天然トコフェロールの含有量(乾燥重量として)は0.5%以上、β-カロテンの含有量が0.1%以上、フィトエン・フィトフルエンの含有量は0.5%以上であることがさらに好ましい。 As the antioxidant, it is preferable to use tomato extract. The tomato extract preferably contains (but is not essential) natural compounds such as β-carotene, tocopherol, phytosterol, phospholipid, phytoene, and phytofluene in addition to lycopene. It is particularly preferable to contain polyphenols, because the interaction as an antioxidant can be expected. The content of lycopene (HPLC method) in the tomato extract is preferably 1% to 50%, more preferably 10% to 30%. This is because a high effect can be expected with a small amount of ingestion. In addition, the content of natural tomatoferol (as dry weight) in the tomato extract is 0.5% or more, the content of β-carotene is 0.1% or more, and the content of phytoene / phytofluene is 0.5% or more. Is more preferable.
トマト抽出物の製造方法としては、特に限定されず、既知の手法を用いて製造することができる。例えば、粉砕されたトマトを遠心分離や静置などの方法で液体成分と繊維成分とに分離し、繊維成分を酢酸エチルやエタノールなどの各種有機溶剤で抽出し、乾燥することにより得ることができる。繊維成分にはリコピンやポリフェノールなどの成分が豊富であるため、効果的に有効成分を抽出可能である。トマトは、粉砕の前後に適宜加熱処理やフィルター処理などが行われても良い。 The method for producing the tomato extract is not particularly limited, and the tomato extract can be produced using a known method. For example, it can be obtained by separating crushed tomatoes into a liquid component and a fiber component by a method such as centrifugation or standing, extracting the fiber component with various organic solvents such as ethyl acetate and ethanol, and drying the tomato. .. Since the fiber component is rich in components such as lycopene and polyphenols, the active ingredient can be effectively extracted. The tomatoes may be appropriately heat-treated or filtered before and after crushing.
ポリフェノールとしては合成物、天然物に拘わらず公知の物を使用することができるが、例えばフラボノイドやカタラーゼ,ペルオキシダーゼ、SOD(スーパーオキシドジスムターゼ),アスコルビン酸、トコフェロールなどが好適に使用される。ポリフェノールとして植物の根、茎、葉、果実、果皮、樹皮などの各種天然物から抽出された抽出エキスを使用することも可能である。 As the polyphenol, known substances can be used regardless of whether they are synthetic or natural products, and for example, flavonoids, catalase, peroxidase, SOD (superoxide dismutase), ascorbic acid, tocopherol and the like are preferably used. It is also possible to use an extract extracted from various natural substances such as roots, stems, leaves, fruits, fruit skins and bark of plants as polyphenols.
ヒシ属植物のエキス、カロテノイド、ポリフェノールの抽出に使用される有機溶媒としては、特に限定されず、1種又は2種以上の有機溶媒が単独又は混合されて使用される。抽出は1回だけでも良く、1種又は2種以上の有機溶媒を使って2回以上に亘って行われても良い。有機溶媒としては、例えばベンゼンなどの芳香族系有機溶剤や、ヘキサンなどの脂肪族系有機溶剤、ケトン、エーテル、アルコール類、酢酸エチル、ジクロロメタン
などの極性溶媒が適宜選択されて使用される。有機溶媒は、最終的に分離され、乾燥エキスのみが分離されることが好ましい。
The organic solvent used for the extraction of trapa plants, carotenoids, and polyphenols is not particularly limited, and one or more organic solvents may be used alone or in combination. Extraction may be performed only once, or may be performed twice or more using one kind or two or more kinds of organic solvents. As the organic solvent, for example, an aromatic organic solvent such as benzene, an aliphatic organic solvent such as hexane, and a polar solvent such as ketone, ether, alcohols, ethyl acetate, and dichloromethane are appropriately selected and used. It is preferred that the organic solvent is finally separated and only the dried extract is separated.
熱水抽出に用いる溶媒としては、水、水溶液、水と混和する任意の1種以上の溶媒と水とを任意の割合で混合した混合溶媒(水性溶媒)を用いることができるが、好ましい抽出溶媒は、水、メタノール、エタノール及びこれらの任意の2以上を任意の割合で混合した水性溶媒であり、特に好ましい抽出溶媒は、水、食品添加物として認められている有機溶媒であるエタノールと水とを任意の割合で混合した水性溶媒である。抽出溶媒の温度は、室温を超え抽出溶媒の沸点以下の任意の温度であってよいが、抽出効率、被抽出物の耐熱性及び揮発性等を考慮して決定されることが好ましい。 As the solvent used for hot water extraction, a mixed solvent (aqueous solvent) in which water, an aqueous solution, or any one or more solvents that are mixed with water and water are mixed at an arbitrary ratio can be used, but a preferable extraction solvent is used. Is an aqueous solvent in which water, methanol, ethanol and any two or more of these are mixed at an arbitrary ratio, and particularly preferable extraction solvents are water, ethanol and water which are organic solvents recognized as food additives. Is an aqueous solvent in which the above is mixed at an arbitrary ratio. The temperature of the extraction solvent may be any temperature above room temperature and below the boiling point of the extraction solvent, but it is preferably determined in consideration of extraction efficiency, heat resistance of the object to be extracted, volatility and the like.
抽出溶媒として水及び水性溶媒を用いる場合には、抽出効率を向上させるために、必要に応じて、酸、塩基、塩等を適宜含んでいてもよい。抽出に用いる水の温度及びpHについては特に制限はないが、pHについては、生体への使用を考慮して中性付近、より具体的にはpH4~9であることが好ましく、pH6~8であることがより好ましい。必要に応じて、抽出効率を向上させるために、加熱した抽出溶媒を用いてもよい。 When water or an aqueous solvent is used as the extraction solvent, an acid, a base, a salt or the like may be appropriately contained in order to improve the extraction efficiency. The temperature and pH of the water used for extraction are not particularly limited, but the pH is preferably near neutral, more specifically pH 4 to 9, and pH 6 to 8 in consideration of use in a living body. It is more preferable to have. If necessary, a heated extraction solvent may be used to improve the extraction efficiency.
熱水抽出は任意の公知の方法により行うことができる。以下、ヒシ科植物について説明するが、各種天然物から抗酸化物のエキスを抽出する場合も同様の手順で行われる。ヒシ科植物の果皮及び果実の一方又は双方を溶媒中で所定時間混合後、ろ過、遠心分離、デカンテーション等により固形分と分離する方法、ソックスレー抽出法等の連続抽出法等の方法を用いることができる。 Hot water extraction can be performed by any known method. Hereinafter, the Trapaceae plant will be described, but the same procedure is used when extracting an antioxidant extract from various natural products. A method of mixing one or both of the pericarp and fruit of a trapaceae plant in a solvent for a predetermined time and then separating them from solids by filtration, centrifugation, decantation, etc., or a continuous extraction method such as a Soxhlet extraction method should be used. Can be done.
ヒシ科植物の果皮の溶媒抽出物から、1又は複数の化合物を分離する前に、高分子量成分や不溶分等を除去するために、透析、限外ろ過、ろ過、カラムクロマトグラフィー等による前処理を行ってもよい。 Pretreatment by dialysis, ultrafiltration, filtration, column chromatography, etc. to remove high molecular weight components, insoluble matter, etc. before separating one or more compounds from the solvent extract of the skin of a trapaceae plant. May be done.
ろ過により不溶分等を除去する場合には、必要に応じて、不純物を除去するために活性炭、ベントナイト、セライト等の吸着剤やろ過助剤を添加してもよい。特に抽出液の状態で用いる場合には、メンブレンフィルター等による除菌ろ過を併せて行うことが好ましい。 When removing insoluble matter or the like by filtration, an adsorbent such as activated carbon, bentonite, or celite or a filtration aid may be added, if necessary, in order to remove impurities. In particular, when it is used in the state of an extract, it is preferable to perform sterilization filtration with a membrane filter or the like.
抗糖化・抗酸化・抗カルボニル化組成物の阻害対象となる反応は、タンパク質のアミノ基と還元糖との反応によるシッフ塩基の生成、アマドリ転位による1,2-エナミノール又は2,3-エンジオールの生成、アマドリ転移生成物の分解及び分解産物とアミノ酸、ペプチド又はタンパク質との重合生成物の生成等の任意の1又は複数の反応などが挙げられる。 The reactions targeted for inhibition of the anti-glycation / anti-oxidation / anti-carbonylation composition are the formation of a shift base by the reaction between the amino group of the protein and the reducing sugar, and the 1,2-enaminol or 2,3-endiol by the Amadori rearrangement. Any one or more reactions such as the production of Amadori rearrangement products and the production of polymerization products of the degradation products with amino acids, peptides or proteins.
抗糖化・抗酸化・抗カルボニル化組成物を担体等と混合することにより、糖尿病及びそれに関連する疾患及び症状に対する治療効果及び予防効果の一方又は双方を有する医薬組成物として用いることができる。医薬組成物のヒト或いは動物に対する投与形態としては、経口、経直腸、非経口(例えば、静脈内投与、筋肉内投与、皮下投与など)等が挙げられ、投与量は、医薬組成物の製剤形態、投与方法、使用目的及びこれに適用される投与対象の年齢、体重、症状によって適宜設定され一義的に決定することは困難であるが、ヒトの場合、一般には製剤中に含有される有効成分の量で、好ましくは成人1日当り0.1~2000mg/日である。もちろん投与量は、種々の条件によって変動するので、上記投与量より少ない量で十分な場合もあるし、或いは上記範囲を超えて必要な場合もある。 By mixing the anti-glycation / antioxidant / anti-carbonylation composition with a carrier or the like, it can be used as a pharmaceutical composition having one or both of a therapeutic effect and a preventive effect on diabetes and related diseases and symptoms. Examples of the administration form of the pharmaceutical composition to humans or animals include oral, transrectal, parenteral (for example, intravenous administration, intramuscular administration, subcutaneous administration, etc.), and the dose is the pharmaceutical composition form. It is difficult to make an appropriate setting according to the administration method, purpose of use, age, body weight, and symptom of the subject to be administered, but in the case of humans, the active ingredient generally contained in the pharmaceutical product. The amount is preferably 0.1 to 2000 mg / day for an adult per day. Of course, since the dose varies depending on various conditions, a dose smaller than the above dose may be sufficient, or a dose exceeding the above range may be required.
経口投与製剤として調製する場合は、錠剤、顆粒剤、散剤、カプセル剤、コーティング剤、液剤、懸濁剤、チュアブル、トローチ等の形態に調製でき、非経口投与製剤にする場合には、注射剤、点滴剤、座薬等の形態に調製することができる。製剤化には、任意の公知の方法を用いることができる。例えば、終末糖化産物生成阻害剤と、製薬学的に許容し得る担体又は希釈剤、安定剤、及びその他の所望の添加剤を配合して、上記の所望の剤形とすることができる。 When prepared as an oral preparation, it can be prepared in the form of tablets, granules, powders, capsules, coatings, liquids, suspensions, chewables, troches, etc., and when it is prepared as a parenteral preparation, it is an injection. , Drips, suppositories, etc. can be prepared. Any known method can be used for the formulation. For example, an advanced glycation end product production inhibitor can be blended with a pharmaceutically acceptable carrier or diluent, stabilizer, and other desired additives to obtain the above-mentioned desired dosage form.
抗糖化・抗酸化・抗カルボニル化組成物を含む食品としては、抗糖化・抗酸化・抗カルボニル化組成物を食品に配合したもの、或いは、カプセル、錠剤等、食品又は健康食品に通常用いられる任意の形態をとることができる。配合される食品の種類に特に制限はなく、例えば、コーヒー、果汁、清涼飲料水、ビール、牛乳、味噌汁、スープ、紅茶、茶、栄養剤、シロップ、マーガリン、ジャム等の液状(流動状)食品、米飯、パン、じゃがいも製品、もち、飴、チョコレート、ふりかけ、ハム、ソーセージ、キャンディー、ガムなどの固形形状食品等の主食、副食、菓子類ならびに調味料に配合することも可能である。用途に応じて、粉末、顆粒、錠剤等の形に成形してもよい。また、必要に応じて、賦形剤、増量剤、結合剤、増粘剤、乳化剤、着色料、香料、食品添加物、調味料等と適宜混合してもよい。 Foods containing anti-glycation / anti-oxidation / anti-carbonylation compositions include foods containing anti-glycation / anti-oxidation / anti-carbonylation compositions, or are usually used for foods or health foods such as capsules and tablets. It can take any form. There are no particular restrictions on the types of foods that can be mixed, for example, liquid (fluid) foods such as coffee, fruit juice, refreshing drinking water, beer, milk, miso juice, soup, black tea, tea, nutritional supplements, syrup, margarine, and jam. It can also be added to main foods such as rice, bread, potato products, rice cakes, candy, chocolate, sprinkles, ham, sausages, candies, gums and other solid foods, side foods, confectionery and seasonings. Depending on the application, it may be formed into powder, granules, tablets or the like. Further, if necessary, it may be appropriately mixed with excipients, bulking agents, binders, thickeners, emulsifiers, coloring agents, flavorings, food additives, seasonings and the like.
また、ヒトの消費に供する食品以外にも、抗糖化・抗酸化・抗カルボニル化組成物を飼料中に混合して、家畜、ペット等の動物に投与する場合には、予め飼料の原料中に混合して、機能性を付与した飼料として調製することができる。また、抗糖化・抗酸化・抗カルボニル化組成物を飼料に添加して投与することもできる。すなわち、抗糖化・抗酸化・抗カルボニル化組成物を有効成分として含む食品は、ブタ、ニワトリ、ウシ、ウマ、ヒツジ等の家畜や、魚類、ペット(イヌ、ネコ、鳥類)等の飼料に添加することにより、安全で、糖尿病及びそれに関連する疾患及び症状の治療効果及び予防効果の一方又は双方を有する機能性飼料として用いることができる。 In addition to foods for human consumption, when an anti-glycation / antioxidant / anti-carbonylation composition is mixed in a feed and administered to animals such as livestock and pets, it is previously added to the feed material. It can be mixed and prepared as a feed with added functionality. Further, the anti-glycation / antioxidant / anti-carbonylation composition can be added to the feed and administered. That is, foods containing an anti-glycation / anti-oxidation / anti-carbonylation composition as an active ingredient are added to livestock such as pigs, chickens, cows, horses and sheep, and feeds such as fish and pets (dogs, cats and birds). As a result, it is safe and can be used as a functional feed having one or both of a therapeutic effect and a preventive effect on diabetes and related diseases and symptoms.
次に、実施例について説明する。 Next, an embodiment will be described.
20歳以上、64歳以下の日本人女性26人を被験者として2つのグループ(実施例1グループと比較例1グループ)に分配し、それぞれ実施例1サンプルと比較例1サンプルを1日1回、12週間に亘って経口摂取させた。2つのグループには、機能を説明したが、自身の属するグループは伝えなかった。以下に、実施例1サンプルと比較例1サンプルの配合を示す。 Twenty-six Japanese women aged 20 to 64 years were divided into two groups (Example 1 group and Comparative Example 1 group), and 1 sample of Example and 1 sample of Comparative Example were given once a day, respectively. It was orally ingested for 12 weeks. I explained the function to the two groups, but did not tell the group to which they belong. The composition of Example 1 sample and Comparative Example 1 sample is shown below.
被験者としては、肌のたるみやシワ、乾燥などの状態が気になる者、右左頬部、右顎部、上背部、上脛部、右足背部のいずれかに毎年10-3月(冬季)に乾燥などによる肌荒れ、又はかゆみ、粉ふきが認められる者を募集した。 Subjects are those who are concerned about skin sagging, wrinkles, dryness, etc., right and left cheeks, right chin, upper back, upper shin, right foot back every October-March (winter) We recruited people who had rough skin due to dryness, itching, or dusting.
ヒシエキスとしては、トウビシの果皮を熱水抽出してから濃縮し、賦形剤としてデキストリンを添加後、90℃×15分間加熱殺菌を行い、濾過後に噴霧乾燥させたものを使用した。乾燥成分中のヒシ果皮抽出エキス成分は67%、デキストリンは33%、全体に対するポリフェノールの含有率は25~40%以上(比色法)、没食子酸4.13%以上、エラグ酸1.15%以上であった。 As the Hishi extract, the peel of Tobishi was extracted with hot water, concentrated, dextrin was added as an excipient, sterilized by heating at 90 ° C. for 15 minutes, filtered, and then spray-dried. Trapa japonica extract component in the dry component is 67%, dextrin is 33%, polyphenol content in the whole is 25-40% or more (colorimetric method), gallic acid 4.13% or more, ellagic acid 1.15%. That was all.
抗酸化物としては、トマト抽出エキスを使用した。リコピンの含有量は15%~30%(HPLC法)、天然トコフェロールの含有量は1.5%以上、フィトエン・フィトフル エンの含有量は1.0%以上、β-カロテンの含有量が0.2%以上であった。 As the antioxidant, tomato extract was used. The content of lycopene is 15% to 30% (HPLC method), the content of natural tocopherol is 1.5% or more, the content of phytoene / phytofluene is 1.0% or more, and the content of β-carotene is 0. It was more than 2%.
トマト抽出エキスとしては、以下の方法で製造されたオレオレジンを使用した。原料となるトマトを粉砕し、それらを熱処理した。粉砕されたトマトを、上清およびパルプに分離した。パルプを溶媒抽出(酢酸エチル)にかけ、リコピン抽出物を溶媒から分離し、それにより、リコピンを含むオレオレジンを得た。使用された溶媒は回収した。 As the tomato extract, oleoresin produced by the following method was used. The tomatoes used as raw materials were crushed and heat-treated. The ground tomatoes were separated into supernatant and pulp. The pulp was subjected to solvent extraction (ethyl acetate) and the lycopene extract was separated from the solvent, thereby giving oleoresin containing lycopene. The solvent used was recovered.
摂取前、摂取4週刊後、摂取8週間後、摂取12週間後のタイミングで被験者の皮膚、血液、尿、身長、体重、血圧、脈拍、抗酸化力(BAP)、酸化ストレス度(d-ROM)などの体調及び健康状態を表す項目について検査、目視による観察及び問診、並びに自覚症状の調査(アンケート)を行った。 Before ingestion, after 4 weeks of ingestion, 8 weeks after ingestion, and 12 weeks after ingestion, the subject's skin, blood, urine, height, weight, blood pressure, pulse, antioxidant power (BAP), oxidative stress level (d-ROM) ) And other items that indicate physical condition and health condition were inspected, visually observed and interviewed, and subjective symptoms were investigated (questionnaire).
試験食の摂取期間は12週間とした。なお、試験期間中は、規則的な生活を心掛け、過激な運動や暴飲暴食を避け、食事や運動に関しては、日常生活と同様の量・質を維持するようにも指導した。 The test meal intake period was 12 weeks. During the test period, he was instructed to keep a regular life, avoid radical exercise and overdrinking, and maintain the same quantity and quality as in daily life regarding diet and exercise.
摂取方法として、被験食を1日1回朝食前に1カプセル、十分な水、またはお湯で摂取させた。朝食前に摂取出来なかった場合は、その日中に摂取するものとするものとし、翌日には持ち越さないようにした。 As a method of ingestion, the test meal was ingested once a day with 1 capsule, sufficient water, or hot water before breakfast. If it could not be taken before breakfast, it should be taken during the day and not carried over to the next day.
1) 有効性に関する試験
肌測定は、下記の項目について摂取開始時、摂取4週後、摂取8週後,摂取12週後の計4回実施した。測定環境は、温度22±2 ℃、湿度50±RH10%で温・湿度を管理し、洗顔後20分間待機させて馴化させた。
1) Efficacy test Skin measurements were performed 4 times in total for the following items: at the start of ingestion, 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion. In the measurement environment, the temperature and humidity were controlled at a temperature of 22 ± 2 ° C and a humidity of 50 ± RH 10%, and after washing the face, the patient was allowed to stand by for 20 minutes to acclimatize.
「皮膚水分蒸散量」の測定部位は3部位を以下の位置で設定した。
1. 右頬部
右目尻からの垂直線と右小鼻からの水平線との交点を測定部位とし、その上部にシールを貼付した。
2. 右脛部
右膝の皿の下部から下方に10cmを測定部位とし、その上部にシールを貼付した。
3. 右足背部
右足の人差し指の付け根から足首側に4 cmを測定部位としてその上部にシールを貼付した。
Three sites were set as the measurement sites for "skin water evaporation amount" at the following positions.
1. The intersection of the vertical line from the right corner of the right cheek and the horizontal line from the right nose was used as the measurement site, and a sticker was attached to the upper part.
2. The measurement site was 10 cm below the bottom of the plate on the right shin and right knee, and a sticker was attached to the top.
3. The back of the right foot A sticker was attached to the upper part of the measurement site, 4 cm from the base of the index finger of the right foot to the ankle side.
「皮膚水分蒸散量」は、TEWAMETER TM 300(Courage+KhazakaElectronic Gmbh)を用い、6部位を1分間連続で測定し、安定した5秒間を採用した。安定した5秒間は連続した5秒間について平均値と標準偏差を算出し、標準偏差の最も小さい区間の平均値を皮膚水分蒸散量として記録した。 For the "skin water evaporation amount", TEWAMETER TM 300 (Courage + KhazakaElectronic Gmbh) was used, and 6 sites were continuously measured for 1 minute, and a stable 5 seconds was adopted. For a stable 5 seconds, the mean value and standard deviation were calculated for 5 consecutive seconds, and the mean value in the section with the smallest standard deviation was recorded as the amount of skin water evaporation.
「肌色測定」は、SPECTROPHOTOMETER(NF333/日本電色工業株式会社)を用い、Lab法による測色:L*値(明度)、a*値(赤み)およびb*値(彩度)について、右前腕内側部位の測定を3回行いその平均値を肌色として記録した。 "Skin color measurement" uses SPECTROPHOTOMETER (NF333 / Nippon Denshoku Industries Co., Ltd.), and color measurement by the Lab method: L * value (brightness), a * value (redness) and b * value (saturation) are on the right. The medial part of the forearm was measured 3 times and the average value was recorded as skin color.
「肌状態撮影」は、VISIA-Generation7(Canfield Scientific)を用い、右顔面を機器の固定台に設置し、被験者には軽く目を閉じさせて安静状態で機器の撮影プログラムにて自動撮影、シミ・赤い部分について解析した。 "Skin condition photography" uses VISIA-Generation7 (Canfield Scientific), the right face is placed on the fixed base of the device, the subject is lightly closed his eyes, and the subject is automatically photographed with the device's imaging program in a resting state.・ The red part was analyzed.
「シミ(Percentile)」は、同年齢100名と比較し、下から数えた順位。その被験者よりも当該測定項目の数値が悪い人が何人いるかを示し、数値が大きい方が良好。最高で「99」となる。値が大きいと、シミが少ないことを示している。「赤い部分(Percentile)」は、同年齢100名と比較し、下から数えた順位。その被験者よりも当該測定項目の数値が悪い人が何人いるかを示し、数値が大きい方が良好。最高で「99」となる。値が大きいと、シミが少ないことを示している。値が大きいと、赤い部分が多いことを示している。「きめ(スコア)」は、解析範囲の面積と色の濃さ情報を数値化したものであり、点数が高いと肌表面に色ムラがあり、点数が低いほど、肌表面に色ムラが無いことを示している。 "Percentile" is the ranking counted from the bottom compared to 100 people of the same age. It indicates how many people have worse numerical values for the measurement item than the subject, and the larger the numerical value, the better. The maximum is "99". A large value indicates that there are few stains. The "red part (Percentile)" is the ranking counted from the bottom compared to 100 people of the same age. It indicates how many people have worse numerical values for the measurement item than the subject, and the larger the numerical value, the better. The maximum is "99". A large value indicates that there are few stains. Larger values indicate more red areas. The "texture (score)" is a numerical value of the area of the analysis range and the color depth information. The higher the score, the more uneven the color on the skin surface, and the lower the score, the less the color unevenness on the skin surface. It is shown that.
「アンケート調査」は、ここ最近の肌の調子について、以下の設問について被験者にweb上で回答させた。
1.肘・膝・かかとの潤い 2. 頸の潤い
左端を「全く潤いがない(想像できる最も悪い状態)」:1とし、右端を「理想的な潤いがある(想像できる最もよい状態)」:100として点数による回答を行った。
The "questionnaire survey" asked the subjects to answer the following questions on the web regarding the recent skin condition.
1. 1. Moisturizing elbows, knees and heels 2. Moisturizing the neck The left end is "no moisturizing (the worst condition you can imagine)": 1 and the right end is "ideal moisturizing (the best condition you can imagine)": 100 I gave an answer based on the score.
アンケート調査は、摂取開始時と摂取4週後、摂取8週後、摂取12週後における摂取開始時からの変化量(差分)を群間でMann-WhitneyのU検定で比較した。なお、統計解析ソフトはDr。 SPSS II for Windows(エス・ピー・エス・エス株式会社)を使用し、いずれの検定においても両側検定で有意水準を5%未満とした。 In the questionnaire survey, the amount of change (difference) from the start of ingestion, 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion was compared between the groups by the Mann-Whitney U test. The statistical analysis software is Dr. SPSS II for Windows (SPSS Co., Ltd.) was used, and the significance level was set to less than 5% in both tests in both tests.
結果を表2に示す。 The results are shown in Table 2.
試験食の摂取率は100%であり、試験期間中の管理事項の不遵守等に該当する被験者はいなかった。その一方で、本試験は2019年末からの新型コロナウイルス感染症(COVID-19)の流行(以下、コロナ禍)下で実施しており、自己都合による途中脱落17名の多くはコロナ禍による自粛を理由としていたことから、試験終了後に最終観察まで参加した被験者にコロナ禍での生活において自粛等を強いられたことによる何らかの不安や精神的なストレスを感じていたかどうかのアンケートを実施し、何かしらのストレスを感じていた被験者については解析除外対象者として取り扱うことを症例検討会にて審議し、最終解析対象者は26名とした。 The intake rate of the test meal was 100%, and there were no subjects who did not comply with the management items during the test period. On the other hand, this test has been conducted under the epidemic of new coronavirus infection (COVID-19) from the end of 2019 (hereinafter referred to as corona-ka), and most of the 17 people who dropped out due to personal reasons are self-restraint due to corona-ka. Because of this, we conducted a questionnaire to see if the subjects who participated until the final observation after the test felt some kind of anxiety or mental stress due to being forced to refrain from living in Korona-ka. The case study group discussed that the subjects who felt the stress of Korona-ka should be treated as the subjects excluded from the analysis, and the final number of subjects for the analysis was 26.
試験食群の被験者13名(男性:2名、女性:11名)の年齢は、51.2±12.3歳(男性:54.5±3.5歳、女性:50.5±13.4歳)であった。プラセボ食群の被験者13名(男性:2名、女性:11名)の年齢は、51.0±10.1歳(男性:59.0±4.2歳、女性:49.5±10.2歳)であった。 The ages of 13 subjects (male: 2 and female: 11) in the test diet group were 51.2 ± 12.3 years (male: 54.5 ± 3.5 years, female: 50.5 ± 13.4 years). The ages of 13 subjects (male: 2 and female: 11) in the placebo diet group were 51.0 ± 10.1 years (male: 59.0 ± 4.2 years, female: 49.5 ± 10.2 years).
「皮膚水分蒸散量:右頬部」では、各観察の値と摂取前の値の差である差分値は試験食群で、摂取4週後において-2.54±5.17、摂取8週後において-5.40±10.12、摂取12週後において-6.41±6.79であった。一方、プラセボ食群で、摂取4週後において0.46±4.83、摂取8週後において0.24±10.29、摂取12週後において3.00±8.08であった。
試験食群とプラセボ食群の群間比較で、摂取12週後(P=0.004)で有意差が認められた。
In "Skin water evaporation: right cheek", the difference value, which is the difference between the value of each observation and the value before ingestion, was -2.54 ± 5.17 after 4 weeks of ingestion and -5.40 after 8 weeks of ingestion in the test meal group. It was ± 10.12 and -6.41 ± 6.79 12 weeks after ingestion. On the other hand, in the placebo diet group, it was 0.46 ± 4.83 after 4 weeks of ingestion, 0.24 ± 10.29 after 8 weeks of ingestion, and 3.00 ± 8.08 after 12 weeks of ingestion.
A significant difference was observed 12 weeks after ingestion (P = 0.004) in the comparison between the test diet group and the placebo diet group.
「皮膚水分蒸散量:右脛」では、各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において-1.36±1.62、摂取8週後において-2.50±1.77、摂取12週後において-3.10±1.93であった。一方、プラセボ食群で、摂取4週後において-1.05±2.60、摂取8週後において-1.19±3.59、摂取12週後において-0.90±2.89であった。試験食群とプラセボ食群の群間比較で、摂取12週後(P=0.032)で有意差が認められた。 In "Skin water evaporation: right shin", the difference value, which is the difference between the value of each observation and the value before ingestion, is -1.36 ± 1.62 after 4 weeks of ingestion and -2.50 after 8 weeks of ingestion in the test meal group. It was ± 1.77 and -3.10 ± 1.93 12 weeks after ingestion. On the other hand, in the placebo diet group, it was -1.05 ± 2.60 after 4 weeks of ingestion, -1.19 ± 3.59 after 8 weeks of ingestion, and -0.90 ± 2.89 after 12 weeks of ingestion. A significant difference was observed 12 weeks after ingestion (P = 0.032) in the comparison between the test diet group and the placebo diet group.
「皮膚水分蒸散量:右足背部」では、各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において-0.02±3.20、摂取8週後において-2.54±3.64、摂取12週後において-1.99±3.67であった。一方、プラセボ食群で、摂取4週後において0.20±3.33、摂取8週後において0.73±2.64、摂取12週後において-0.57±3.03であった。試験食群とプラセボ食群の群間比較で、摂取8週後(P=0.015)で有意差が認められた。 In "Skin water evaporation: back of right foot", the difference value, which is the difference between the value of each observation and the value before ingestion, was -0.02 ± 3.20 after 4 weeks of ingestion and -2.54 after 8 weeks of ingestion in the test meal group. It was ± 3.64 and -1.99 ± 3.67 12 weeks after ingestion. On the other hand, in the placebo diet group, it was 0.20 ± 3.33 after 4 weeks of ingestion, 0.73 ± 2.64 after 8 weeks of ingestion, and -0.57 ± 3.03 after 12 weeks of ingestion. A significant difference was observed 8 weeks after ingestion (P = 0.015) in the comparison between the test diet group and the placebo diet group.
「肌色測定:L*値 明度」
各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において0.214±1.114、摂取8週後において0.437±1.002、摂取12週後において0.638±0.883であった。一方、プラセボ食群で、摂取4週後において-0.086±0.958、摂取8週後において-0.515±0.834、摂取12週後において0.086±0.760であった。試験食群とプラセボ食群の群間比較で、摂取8週後(P=0.015)で有意差が認められた。なお、a*値(赤み)、b*値(彩度)においては、有意差は確認されなかった。
"Skin color measurement: L * value brightness"
The difference value, which is the difference between the value of each observation and the value before ingestion, was 0.214 ± 1.114 after 4 weeks of ingestion, 0.437 ± 1.002 after 8 weeks of ingestion, and 0.638 ± 0.883 after 12 weeks of ingestion in the test meal group. rice field. On the other hand, in the placebo diet group, it was -0.086 ± 0.958 after 4 weeks of ingestion, -0.515 ± 0.834 after 8 weeks of ingestion, and 0.086 ± 0.760 after 12 weeks of ingestion. A significant difference was observed 8 weeks after ingestion (P = 0.015) in the comparison between the test diet group and the placebo diet group. No significant difference was confirmed in the a * value (redness) and b * value (saturation).
「肌状態撮影:シミ(Percentile)」において、各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において-3.92±18.92、摂取8週後において2.23±14.28、摂取12週後において3.69±12.52であった。一方、プラセボ食群で、摂取4週後において-5.54±12.54、摂取8週後において-7.46±15.03、摂取12週後において-6.54±12.49であった。試験食群とプラセボ食群の群間比較で、摂取12週後(P=0.048)で有意差が認められた。 In "Skin condition photography: Percentile", the difference value, which is the difference between the value of each observation and the value before ingestion, was -3.92 ± 18.92 after 4 weeks of ingestion and 2.23 after 8 weeks of ingestion in the test meal group. It was ± 14.28 and 3.69 ± 12.52 12 weeks after ingestion. On the other hand, in the placebo diet group, it was -5.54 ± 12.54 after 4 weeks of ingestion, -7.46 ± 15.03 after 8 weeks of ingestion, and -6.54 ± 12.49 after 12 weeks of ingestion. A significant difference was observed 12 weeks after ingestion (P = 0.048) in the comparison between the test diet group and the placebo diet group.
「肌状態撮影:きめ(スコア))」において、各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において0.008±1.332、摂取8週後において-0.530±1.709、摂取12週後において-0.177±2.760であった。一方、プラセボ食群で、摂取4週後において1.305±1.926、摂取8週後において1.187±2.143、摂取12週後において1.038±2.178であった。試験食群とプラセボ食群の群間比較で、摂取8週後(P=0.033)で有意差が認められた。 In "Skin condition photography: texture (score)), the difference value, which is the difference between the value of each observation and the value before ingestion, is 0.008 ± 1.332 at 4 weeks after ingestion and 0.008 ± 1.332 after 8 weeks of ingestion in the test meal group- It was 0.530 ± 1.709 and -0.177 ± 2.760 12 weeks after ingestion. On the other hand, in the placebo diet group, it was 1.305 ± 1.926 after 4 weeks of ingestion, 1.187 ± 2.143 after 8 weeks of ingestion, and 1.038 ± 2.178 after 12 weeks of ingestion. A significant difference was observed 8 weeks after ingestion (P = 0.033) in the comparison between the test diet group and the placebo diet group.
「肌状態撮影:赤い部分(Percentile)」において、各観察の値と摂取前の値の差である差分値は、試験食群で、摂取4週後において7.85±16.01、摂取8週後において10.54±19.95、摂取12週後において2.46±21.46であった。一方、プラセボ食群で、摂取4週後において-4.54±7.86、摂取8週後において-1.69±6.07、摂取12週後において-3.92±7.54であった。試験食群とプラセボ食群の群間比較で、摂取4週後(P=0.022)で有意差が認められた。 In "Skin condition photography: red part (Percentile)", the difference value, which is the difference between the value of each observation and the value before ingestion, is 7.85 ± 16.01 after 4 weeks of ingestion and 10.54 after 8 weeks of ingestion in the test meal group. It was ± 19.95 and 2.46 ± 21.46 12 weeks after ingestion. On the other hand, in the placebo diet group, it was -4.54 ± 7.86 after 4 weeks of ingestion, -1.69 ± 6.07 after 8 weeks of ingestion, and -3.92 ± 7.54 after 12 weeks of ingestion. A significant difference was observed 4 weeks after ingestion (P = 0.022) in the comparison between the test diet group and the placebo diet group.
有効性を確認するため、被験者の血液を採取し、糖化物およびカルボニル化タンパクの指標マーカーである血漿ペントシジン(Pentosidine)を測定した。血液採取は、摂取開始時、摂取4週後、摂取8週後、摂取12週後に実施した。摂取4週後が-0.0037±0.00186、摂取8週後が-0.0073±0.0169、摂取12週後が-0.0163±0.0112であり、徐々に数値の減少が大きくなっていた。一方、プラセボ食群で、摂取4週後が0.0198±0.0229、摂取8週後 0.0115±0.0255、摂取12週後が0.0019±0.0169であった。試験食群とプラセボ食群の群間比較で、摂取4週後(P=0.008)、摂取8週後(P=0.036)、摂取12週後(P=0.004)で有意差が認められた。 To confirm efficacy, subjects' blood was taken and plasma pentosidine, an indicator marker for saccharified and carbonylated proteins, was measured. Blood was collected at the start of ingestion, 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion. It was -0.0037 ± 0.00186 after 4 weeks of ingestion, -0.0073 ± 0.0169 after 8 weeks of ingestion, and -0.0163 ± 0.0112 after 12 weeks of ingestion, and the decrease in the values gradually increased. On the other hand, in the placebo diet group, it was 0.0198 ± 0.0229 after 4 weeks of ingestion, 0.0115 ± 0.0255 after 8 weeks of ingestion, and 0.0019 ± 0.0169 after 12 weeks of ingestion. A significant difference was observed between the test diet group and the placebo diet group at 4 weeks after ingestion (P = 0.008), 8 weeks after ingestion (P = 0.036), and 12 weeks after ingestion (P = 0.004).
安全性を確認するため、摂取開始時、摂取4週後、摂取8週後、摂取12週後に「体重、BMI、血圧、脈拍」、「血液検査(白血球数、赤血球数、血色素量、ヘマトクリット、MCV、MCH、MCHC、血小板数)と血液生化学的検査(総コレステロール、LDLコレステロール、HDLコレステロール、中性脂肪、総蛋白、アルブミン、尿素窒素、クレアチニン、尿酸、AST、ALT、γ-GT、乳酸脱水素酵素、クレアチニンキナーゼ、血糖、HbA1c、酸化LDL)及び尿検査(蛋白、糖、ウロビリノーゲン、ビリルビン、比重、pH、ケトン体、潜血)」を行ったが、いずれも有意差はなく、標準値の範囲を超えてしまうような大きな数値変動もなく、安全性が確認された。 To confirm safety, "weight, BMI, blood pressure, pulse", "blood test (leukocyte count, red blood cell count, blood pigment level, hematocrit, hematocrit," at the start of ingestion, 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion. MCV, MCH, MCHC, red blood cell count) and blood biochemical tests (total cholesterol, LDL cholesterol, HDL cholesterol, neutral fat, total protein, albumin, urea nitrogen, creatinine, uric acid, AST, ALT, γ-GT, lactic acid Dehydrogenase, creatinine kinase, blood glucose, HbA1c, oxidized LDL) and urine test (protein, sugar, urobilinogen, bilirubin, specific gravity, pH, ketone body, occult blood) ”were performed, but there was no significant difference in any of them, and the standard values. The safety was confirmed without large numerical fluctuations that would exceed the range of.
その他、被験者の体調変化について、毎日アンケート回答を行い、被験者の体調変化を確認した。特段大きな事象は確認されず、安全性が確認された。 In addition, we conducted daily questionnaire responses regarding changes in the physical condition of the subjects and confirmed the changes in the physical condition of the subjects. No significant event was confirmed, and safety was confirmed.
<動作及び効果>
以上の構成によれば、本願発明の組成物は、
ヒシ属植物の加工物と活性酸素を除去可能な抗酸化物とを含有するようにした。
<Operation and effect>
According to the above configuration, the composition of the present invention is:
It was made to contain a processed product of Trapa japonica and an antioxidant capable of removing active oxygen.
これにより、ヒシ属植物が有する抗糖化・抗カルボニル化の作用に加えて、反応の原因となる活性酸素を除去することができるため、老化の3大因子である糖化・カルボニル化・酸化を抑制し、高いアンチエイジング効果を呈することができる。 As a result, in addition to the anti-glycation and anti-carbonylation effects of Trapa plants, active oxygen that causes the reaction can be removed, thus suppressing saccharification, carbonylation, and oxidation, which are the three major factors of aging. However, it can exhibit a high anti-aging effect.
組成物において、ヒシ属植物の加工物がトウビシ、オニビシ、ツノナシビシ、ヒメビシ、ヒシ、及びトラパ・ナタンスからなる群より選択される少なくとも一つのヒシ属植物の加工物であることを特徴とする。 In the composition, the processed product of the genus Trapa is a processed product of the genus Trapa selected from the group consisting of trapa natans, trapa natans, trapa incisa, trapa incisa, trapa japonica, and trapa natans.
これにより、ヒシ属植物に特徴的なヒシポリフェノールのメイラード阻害効果により、効果的に糖化・カルボニル化・酸化を抑制することができる。 As a result, saccharification, carbonylation, and oxidation can be effectively suppressed by the Maillard inhibitory effect of Trapa japonica, which is characteristic of Trapa japonica plants.
組成物において、
ヒシ属植物の加工物がヒシ属植物の果皮の粉砕物及び/又は抽出物である。
In the composition
The processed product of the genus Trapa is a crushed product and / or an extract of the peel of the genus Trapa.
これにより、ヒシ属植物に特徴的なヒシポリフェノールの豊富な果皮から、効率良くヒシポリフェノールを摂取することができる。 As a result, the trapa japonica can be efficiently ingested from the pericarp rich in trapa japonica, which is characteristic of trapa japonica plants.
組成物において、前記活性酸素は、
スーパーオキシドアニオン(O2)、ヒドロキシラジカル(・OH)、一酸化窒素ラジカル(NO・)、次亜塩素酸イオン(ClO)、過酸化水素(H2O2)、一重項酸素(1O2)など、フリーラジカルを保有する又はフリーラジカルを容易に生成可能な状態にある低分子の酸素化合物であることを特徴とする。
In the composition, the active oxygen is
Free radicals such as superoxide anion (O2), hydroxy radical (・ OH), nitrogen monoxide radical (NO ・), hypochlorite ion (ClO), hydrogen peroxide (H2O2), singlet oxygen (1O2) It is characterized by being a low molecular weight oxygen compound in a state of possession or a state in which free radicals can be easily generated.
これにより、全身にくまなく存在する活性酸素を低減し、糖化・カルボニル化・酸化反応を抑制することができる。 As a result, active oxygen present throughout the whole body can be reduced, and saccharification, carbonylation, and oxidation reactions can be suppressed.
組成物において、前記抗酸化物は、カロテノイドである
ことを特徴とする。
In the composition, the antioxidant is characterized by being a carotenoid.
これにより、抗酸化物として、抗酸化能力の高いカロテノイドを使用できるため、起因物質を低減することができ、糖化・カルボニル化・酸化反応の反応を効果的に抑制できる。 As a result, since carotenoids having high antioxidant capacity can be used as the antioxidant, the causative substance can be reduced, and the reactions of saccharification, carbonylation, and oxidation reaction can be effectively suppressed.
組成物において、
前記抗酸化物は、トマト抽出エキスであることを特徴とする。
In the composition
The antioxidant is characterized by being a tomato extract.
これにより、ヒシ属植物とトマト抽出エキスとからなる、天然由来、かつアンチエイジング効果の高い組成物を得ることが出来る。 This makes it possible to obtain a naturally-derived composition having a high anti-aging effect, which is composed of a trapa japonica plant and a tomato extract.
組成物において、前記抗酸化物は、
カロテノイドとポリフェノールとを含有することを特徴とする。
In the composition, the antioxidant is
It is characterized by containing carotenoids and polyphenols.
これにより、多種類の抗酸化物の効果により、個人差を低減し、一段と多くの人に効果がある組成物を提供できる。 As a result, it is possible to provide a composition that is effective for more people by reducing individual differences due to the effects of various types of antioxidants.
組成物において、前記抗酸化物は、
ポリフェノールであることを特徴とする。
In the composition, the antioxidant is
It is characterized by being a polyphenol.
これにより、多種類のポリフェノールの複合的な作用により、アンチエイジング効果の高い組成物を得ることが出来る。 As a result, a composition having a high anti-aging effect can be obtained by the combined action of many kinds of polyphenols.
組成物において、
前記組成物が飲食品、医薬用、サプリメントである
ことを特徴とする。
In the composition
The composition is characterized by being a food or drink, a medicinal product, or a supplement.
これにより、アンチエイジング効果を有する組成物を個人の状態や症状に応じた適切な形態で摂取することができる。 Thereby, the composition having an anti-aging effect can be ingested in an appropriate form according to an individual's condition and symptom.
前記組成物がソフトカプセル、ハードカプセル、液剤、ゼリー、グミ、錠剤、顆粒、粉末飲料、散剤であることを特徴とする。 The composition is characterized by being a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummies, a tablet, a granule, a powdered beverage, or a powder.
これにより、アンチエイジング効果を有する組成物を、個人の好みや体調などに応じた適切な形態で摂取することができる。 Thereby, the composition having an anti-aging effect can be ingested in an appropriate form according to an individual's taste, physical condition and the like.
本発明は、老化予防、肌質改善などに効果を有するサプリメント剤などに適用することができる。
The present invention can be applied to supplements and the like that are effective in preventing aging and improving skin quality.
Claims (9)
を含有することを特徴とする組成物。 A composition characterized by containing a processed product of the genus Trapa and an extract of tomato extract.
リコピンを1~50%含有する
ことを特徴とする請求項1に記載の組成物。 The tomato extract is
The composition according to claim 1, wherein the composition contains 1 to 50% of lycopene.
リコピン以外の成分としてポリフェノールを含有する
ことを特徴とする請求項2に記載の組成物。 The tomato extract is
The composition according to claim 2, wherein the composition contains polyphenol as a component other than lycopene.
酢酸エチルにより抽出された
ことを特徴とする請求項1に記載の組成物。 The tomato extract is
The composition according to claim 1, wherein the composition is extracted with ethyl acetate.
ことを特徴とする請求項1に記載の組成物。 The first aspect of claim 1, wherein the processed product of the genus Trapa is a processed product of the genus Trapa selected from the group consisting of trapa natans, trapa natans, trapa incisa, trapa incisa, trapa japonica, and trapa natans. Composition.
ことを特徴とする請求項1又は5に記載の組成物。 The composition according to claim 1 or 5, wherein the processed product of the genus Trapa is a pulverized product and / or an extract of the peel of the genus Trapa.
ことを特徴とする請求項1~6のいずれか一項に記載の組成物。 The composition according to any one of claims 1 to 6, which is for food and drink or for pharmaceutical purposes.
ことを特徴とする請求項1~6のいずれか一項に記載の組成物。 The composition according to any one of claims 1 to 6, wherein the composition is for supplements.
ことを特徴とする請求項1~8のいずれか一項に記載の組成物。
The composition according to any one of claims 1 to 8, wherein the composition is a soft capsule, a hard capsule, a liquid preparation, a jelly, a gummy candy, a tablet, a granule, a powdered beverage, or a powder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020191245 | 2020-11-17 | ||
JP2020191245 | 2020-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022080275A true JP2022080275A (en) | 2022-05-27 |
Family
ID=81731393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021175072A Pending JP2022080275A (en) | 2020-11-17 | 2021-10-26 | Composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2022080275A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1135444A (en) * | 1997-07-18 | 1999-02-09 | Nikko Chem Kk | Novel cosmetic |
JP2003063976A (en) * | 2001-08-28 | 2003-03-05 | Ichimaru Pharcos Co Ltd | Water chestnut extract-containing cosmetic composition |
JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
JP2017141217A (en) * | 2016-02-05 | 2017-08-17 | 参天製薬株式会社 | Composition containing xanthophyll and processed product of trapa plants |
JP2020143034A (en) * | 2019-03-08 | 2020-09-10 | カイゲンファーマ株式会社 | Maillard reaction inhibitor and ages cross-link cleavage accelerator |
-
2021
- 2021-10-26 JP JP2021175072A patent/JP2022080275A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1135444A (en) * | 1997-07-18 | 1999-02-09 | Nikko Chem Kk | Novel cosmetic |
JP2003063976A (en) * | 2001-08-28 | 2003-03-05 | Ichimaru Pharcos Co Ltd | Water chestnut extract-containing cosmetic composition |
JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
JP2017141217A (en) * | 2016-02-05 | 2017-08-17 | 参天製薬株式会社 | Composition containing xanthophyll and processed product of trapa plants |
JP2020143034A (en) * | 2019-03-08 | 2020-09-10 | カイゲンファーマ株式会社 | Maillard reaction inhibitor and ages cross-link cleavage accelerator |
Non-Patent Citations (4)
Title |
---|
AMAZON, 2013.10.24 [検索日 2022.08.24], インターネット:<URL:HTTPS://WWW.AMAZON.CO.JP/%E3%83%95%E3%8, JPN6022036235, ISSN: 0005100472 * |
AMAZON, 2018.02.12 [検索日 2022.08.24], インターネット:<URL:HTTPS://WWW.AMAZON.CO.JP/DP/B09VG9V6B9/, JPN6022036234, ISSN: 0005100471 * |
AMAZON, 2020.06.30 [検索日 2022.08.24], インターネット:<URL:HTTPS://WWW.AMAZON.CO.JP/%E3%82%B7%E3%8, JPN6022036233, ISSN: 0005100469 * |
日本食品工業学会誌, vol. 19, no. 8, JPN6022036232, 1972, pages 365 - 370, ISSN: 0005100470 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2006014028A1 (en) | Sweet potato stem and leaf extract and use thereof | |
KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
JP2005008572A (en) | Lipase inhibitor | |
WO2006075865A1 (en) | Skin-condition improving composition comprising vaccinium uliginosum extract and method for preparation thereof | |
JP2004075638A (en) | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure | |
JP6902806B2 (en) | Beet juice with enhanced intestinal absorption rate and its manufacturing method and applications | |
CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
CN101925359A (en) | Composition | |
JP4358957B2 (en) | Agent for scavenging or reducing free radicals or active oxygen | |
CA3091105A1 (en) | Compositions from cacao pericarp and methods of producing and using them | |
JP4974116B2 (en) | Foods and beverages and pharmaceuticals containing loquat leaf extract | |
JP2003325135A (en) | Health food | |
JP6735224B2 (en) | Activator of glucose metabolism in astrocytes | |
US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
KR102571249B1 (en) | Composition for promoting hair growth or preventing hair loss, containing sprout barley extract as an active ingredient | |
KR100699782B1 (en) | Food composition for improving liver function comprising a Lonicera caerulea L. var. edulis extract | |
KR101616811B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
JP2010159283A (en) | Proanthocyanidin-containing composition | |
JP6844857B2 (en) | A skin moisturizing composition containing acacia bark-derived products | |
JP2002186453A (en) | Olive extract-containing food/drink | |
JP2003334022A (en) | Endurance-improving food composition | |
KR20090007512A (en) | Emotional tea with spicy, sweety collagen blueberry vita green tea | |
JP2022080275A (en) | Composition | |
JP2019073476A (en) | Agent for atp production promotion | |
CN101528245A (en) | Composition for amelioration of skin condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220727 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230517 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230524 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230707 |